Human epidermal growth factor-TF fusion protein and use thereof
The present invention relates to a novel human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein and a use thereof. More particularly, the human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein of the present invention has fused therein: a signal peptide of a Bacillus subtilis -derived xylanase; a human epidermal growth factor (hEGF); and an Escherichia coli -derived trigger factor (TF). Therefore, the present invention not only enhances the water solubility and expression rate of a target protein, but also notably enhances useful effects such as the effects of increasing skin cell growth and healing a wound, and thus may be widely used in various industries as an active ingredient for a functional cosmetic composition and a pharmaceutical composition.
1 . A human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein consisting of the amino acid sequence of SEQ ID NO: 11.
2 . A method for producing the hEGF-TF fusion protein of claim 1 , the method comprising steps of:
(a) preparing a recombinant expression vector comprising a nucleic acid construct comprising a nucleotide sequence encoding the hEGF-TF fusion protein of claim 1 ;
(b) preparing a transformant by introducing the recombinant expression vector of the step (a) into a microorganism; and
(c) culturing the transformant of the step (b) to produce the hEGF-TF fusion protein.
3 . The method of claim 2 , wherein the step (c) further comprises step of culturing the transformant and replacing the medium before producing the hEGF-TF fusion protein.
4 . A method for treating a skin disease, the method comprising administering a composition comprising the hEGF-TF fusion protein of claim 1 to a subject having the skin disease.
5 . The method of claim 4 , wherein the composition is a pharmaceutical composition for treating a skin disease.
6 . The method of claim 4 , wherein the composition is a food composition for treating a skin disease.
7 . The method of claim 4 , wherein the composition is a cosmetic composition for treating a skin disease.